456 related articles for article (PubMed ID: 12542733)
41. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
[TBL] [Abstract][Full Text] [Related]
42. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
Front Immunol; 2019; 10():40. PubMed ID: 30778345
[No Abstract] [Full Text] [Related]
43. Predictive factors of response to IVIG in pediatric immune thrombocytopenic purpura.
Higashide Y; Hori T; Yoto Y; Kabutoya H; Honjo S; Sakai Y; Nojima M; Yoda M; Yamamoto M; Tsutsumi H
Pediatr Int; 2018 Apr; 60(4):357-361. PubMed ID: 29297955
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Lioger B; Maillot F; Ternant D; Passot C; Paintaud G; Bejan-Angoulvant T
J Pediatr; 2019 Jan; 204():225-233.e8. PubMed ID: 30314658
[TBL] [Abstract][Full Text] [Related]
45. Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.
Ballow M
Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):22-5. PubMed ID: 19630866
[TBL] [Abstract][Full Text] [Related]
46. Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both.
Gereige RS; Barrios NJ
P R Health Sci J; 2000 Mar; 19(1):15-8. PubMed ID: 10761200
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.
Melamed IR; Borte M; Trawnicek L; Kobayashi AL; Kobayashi RH; Knutsen A; Gupta S; Smits W; Pituch-Noworolska A; Strach M; Pulka G; Ochs HD; Moy JN
Eur J Pharm Sci; 2018 Jun; 118():80-86. PubMed ID: 29522908
[TBL] [Abstract][Full Text] [Related]
48. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
[TBL] [Abstract][Full Text] [Related]
49. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
[TBL] [Abstract][Full Text] [Related]
50. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
51. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials
.
Frenzel W; Wietek S; Svae TE; Debes A; Svorc D
Int J Clin Pharmacol Ther; 2016 Nov; 54(11):847-855. PubMed ID: 27719744
[TBL] [Abstract][Full Text] [Related]
52. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
54. The experience of Flebogammadif® in primary immune thrombocytopenia.
Julia A
Clin Exp Immunol; 2011 Jun; 164 Suppl 2(Suppl 2):12-5. PubMed ID: 21466547
[TBL] [Abstract][Full Text] [Related]
55. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.
Blanchette V; Imbach P; Andrew M; Adams M; McMillan J; Wang E; Milner R; Ali K; Barnard D; Bernstein M
Lancet; 1994 Sep; 344(8924):703-7. PubMed ID: 7915773
[TBL] [Abstract][Full Text] [Related]
56. [Treatment of immune thrombocytopenic purpura in Pediatrics. Therapeutic efficacy of a regional intravenous immunoglobulin G].
Buteler C; Colombo H; Gabosi G; Manfredi MJ; Montero S; Pasquali MA; Rougier C; Sisti AM
Medicina (B Aires); 2001; 61(5 Pt 1):522-8. PubMed ID: 11721317
[TBL] [Abstract][Full Text] [Related]
57. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases.
Dumas T; Berry NS; Wolfsegger M; Jolles S; McCoy B; Yel L
Int Immunopharmacol; 2019 Jun; 71():404-410. PubMed ID: 30952104
[TBL] [Abstract][Full Text] [Related]
58. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
[TBL] [Abstract][Full Text] [Related]
59. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group.
Warrier I; Bussel JB; Valdez L; Barbosa J; Beardsley DS
J Pediatr Hematol Oncol; 1997; 19(3):197-201. PubMed ID: 9201140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
